Roche (OTCMKTS:RHHBY) Upgraded to “Strong-Buy” at Sanford C. Bernstein

Roche (OTCMKTS:RHHBY) was upgraded by equities research analysts at Sanford C. Bernstein to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Roche Trading Down 1.5 %

Shares of Roche stock opened at $39.25 on Thursday. Roche has a 52 week low of $29.20 and a 52 week high of $42.43. The business’s fifty day simple moving average is $36.14 and its 200-day simple moving average is $38.25. The company has a quick ratio of 0.97, a current ratio of 1.26 and a debt-to-equity ratio of 0.86.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Kornitzer Capital Management Inc. KS lifted its holdings in Roche by 1.3% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 136,923 shares of the company’s stock worth $5,490,000 after buying an additional 1,798 shares in the last quarter. Bard Financial Services Inc. raised its stake in shares of Roche by 37.7% in the fourth quarter. Bard Financial Services Inc. now owns 110,850 shares of the company’s stock valued at $3,866,000 after acquiring an additional 30,350 shares in the last quarter. Diversified Trust Co boosted its holdings in Roche by 1.2% in the fourth quarter. Diversified Trust Co now owns 60,453 shares of the company’s stock valued at $2,130,000 after purchasing an additional 711 shares during the period. Hantz Financial Services Inc. grew its stake in Roche by 0.9% during the 4th quarter. Hantz Financial Services Inc. now owns 33,708 shares of the company’s stock worth $1,176,000 after purchasing an additional 305 shares in the last quarter. Finally, Confluence Investment Management LLC increased its holdings in Roche by 26.3% during the 4th quarter. Confluence Investment Management LLC now owns 13,981 shares of the company’s stock worth $488,000 after purchasing an additional 2,910 shares during the period.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.